MD4490B1 - Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin - Google Patents

Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin Download PDF

Info

Publication number
MD4490B1
MD4490B1 MDA20140084A MD20140084A MD4490B1 MD 4490 B1 MD4490 B1 MD 4490B1 MD A20140084 A MDA20140084 A MD A20140084A MD 20140084 A MD20140084 A MD 20140084A MD 4490 B1 MD4490 B1 MD 4490B1
Authority
MD
Moldova
Prior art keywords
pharmaceutical compositions
same
compositions containing
indolizine derivatives
preparing
Prior art date
Application number
MDA20140084A
Other languages
English (en)
Russian (ru)
Other versions
MD4490C1 (ro
MD20140084A2 (en
Inventor
Дигуарье Тьерри Ле
Патрик Касара
Жером-Бенуа Старк
Жан-Мишель ХЕНЛИН
Джеймс Эдвард Пол Дэвидсон
Джеймс Брук МЮРРЕЙ
Кристофер Джон Грэм
Ай-Джен ЧЕНЬ
Оливье Женест
Джон Хикман
Стефан Депиль
Тиран Арно Ле
Миклош Ньергеш
Нантей Гийом Де
Original Assignee
Les Laboratoires Servier
Vernalis (R&D) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier, Vernalis (R&D) Ltd filed Critical Les Laboratoires Servier
Publication of MD20140084A2 publication Critical patent/MD20140084A2/ro
Publication of MD4490B1 publication Critical patent/MD4490B1/ro
Publication of MD4490C1 publication Critical patent/MD4490C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Invenţia se referă la noi compuşi indolizinici care pot fi utilizaţi în tratamentul bolilor oncologice şi celor legate de apoptoză.Se revendică compuşi cu formula (I) şi un procedeu de obţinere a lor:unde Ra, Rb, Rc, Rd, R1, R2, R3, R4, R5,, X, Y şi Het sunt definiţi în descriere.De asemenea se revendică compoziţii farmaceutice care conţin un compus cu formula (I) sau o sare de adiţie a acestuia cu un acid sau o bază acceptabilă farmaceutic; şi utilizarea compoziţiilor farmaceutice respective în fabricarea medicamentelor.
MDA20140084A 2012-01-24 2013-01-23 Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin MD4490C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1200193A FR2986002B1 (fr) 2012-01-24 2012-01-24 Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR2013/050136 WO2013110890A1 (fr) 2012-01-24 2013-01-23 Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (3)

Publication Number Publication Date
MD20140084A2 MD20140084A2 (en) 2014-12-31
MD4490B1 true MD4490B1 (ro) 2017-06-30
MD4490C1 MD4490C1 (ro) 2018-01-31

Family

ID=47714428

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20140084A MD4490C1 (ro) 2012-01-24 2013-01-23 Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin

Country Status (51)

Country Link
US (3) US9120791B2 (ro)
EP (1) EP2807159B1 (ro)
JP (1) JP5978317B2 (ro)
KR (1) KR101946911B1 (ro)
CN (1) CN104144930B (ro)
AP (1) AP4028A (ro)
AR (1) AR089774A1 (ro)
AU (1) AU2013213474B2 (ro)
BR (1) BR112014018165B1 (ro)
CA (1) CA2861160C (ro)
CL (1) CL2014001829A1 (ro)
CR (1) CR20140311A (ro)
CU (1) CU20140089A7 (ro)
CY (1) CY1118547T1 (ro)
DK (1) DK2807159T3 (ro)
DO (1) DOP2014000156A (ro)
EA (1) EA026641B1 (ro)
EC (1) ECSP14008606A (ro)
ES (1) ES2616679T3 (ro)
FR (1) FR2986002B1 (ro)
GE (1) GEP201606540B (ro)
GT (1) GT201400142A (ro)
HK (1) HK1203507A1 (ro)
HR (1) HRP20170153T1 (ro)
HU (1) HUE031895T2 (ro)
IL (1) IL233663B (ro)
JO (1) JO3195B1 (ro)
LT (1) LT2807159T (ro)
MA (1) MA35903B1 (ro)
MD (1) MD4490C1 (ro)
ME (1) ME02601B (ro)
MX (1) MX351206B (ro)
MY (1) MY172811A (ro)
NI (1) NI201400081A (ro)
NZ (1) NZ626942A (ro)
PE (1) PE20141405A1 (ro)
PH (1) PH12014501488A1 (ro)
PL (1) PL2807159T3 (ro)
PT (1) PT2807159T (ro)
PY (1) PY1302437A (ro)
RS (1) RS55739B1 (ro)
RU (1) RU2646223C2 (ro)
SA (1) SA113340219B1 (ro)
SG (1) SG11201403748RA (ro)
SI (1) SI2807159T1 (ro)
TN (1) TN2014000283A1 (ro)
TW (1) TWI476198B (ro)
UA (1) UA112215C2 (ro)
UY (1) UY34578A (ro)
WO (1) WO2013110890A1 (ro)
ZA (1) ZA201405101B (ro)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2986002B1 (fr) 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008978A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
FR3008976A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
FR3008979B1 (fr) 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016190847A1 (en) * 2015-05-26 2016-12-01 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2017013271A1 (en) * 2015-07-23 2017-01-26 Les Laboratoires Servier Combination of an inhibitor of phosphatidylinositol 3-kinase delta and a bcl-2 inhibitor, uses and pharmaceutical compositions thereof
UY37316A (es) 2016-07-07 2018-01-31 Servier Lab Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer
UY37342A (es) 2016-07-22 2018-01-31 Servier Lab Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
WO2019008126A1 (en) 2017-07-06 2019-01-10 Les Laboratoires Servier NOVEL CRYSTALLINE FORM OF BCL-2 INHIBITOR, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
WO2019020070A1 (zh) 2017-07-27 2019-01-31 江苏恒瑞医药股份有限公司 哌嗪并杂芳基类衍生物、其制备方法及其在医药上的应用
FR3072679B1 (fr) * 2017-10-25 2020-10-30 Servier Lab Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2019134970A1 (en) 2018-01-05 2019-07-11 Les Laboratoires Servier Novel salts of a bcl-2 inhibitor,related crystalline forms,method for preparing the same and pharmaceutical compositions containing the same
CA3087262A1 (en) 2018-01-10 2019-07-18 Recurium Ip Holdings, Llc Benzamide compounds
BR112020016551A2 (pt) 2018-02-16 2020-12-22 Abbvie Inc. Inibidores de bcl-2 seletivos em combinação com anticorpo anti-pd-1 ou anti-pd-l1 para o tratamento de cânceres
DK3969000T3 (da) 2019-05-14 2023-11-27 Servier Lab Bcl-2 inhibitorer til anvendelse i behandling af en bcl-2 medieret cancer, der bærer gly101val-mutationen
PY2020118A (es) 2019-05-20 2022-10-27 Servier Lab Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
CN117136076A (zh) 2020-11-24 2023-11-28 诺华股份有限公司 Mcl-1抑制剂抗体药物缀合物和使用方法
KR20230170644A (ko) 2021-02-02 2023-12-19 르 라보레또레 쎄르비에르 선택적 bcl-xl protac 화합물 및 사용 방법
BR112023017344A2 (pt) 2021-03-12 2023-09-26 Eil Therapeutics Inc Compostos que têm tetra-hidroindolizina-1-carboxamida como inibidores de bcl-2
US20250115577A1 (en) * 2021-12-29 2025-04-10 Eil Therapeutics, Inc. BCL-2 Inhibitors
US20250387504A1 (en) 2022-05-20 2025-12-25 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
US20250339547A1 (en) 2022-05-20 2025-11-06 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
EP4676540A1 (en) 2023-03-10 2026-01-14 Novartis AG Panras inhibitor antibody-drug conjugates and methods of use thereof
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
TW202540185A (zh) 2023-11-22 2025-10-16 法商施維雅藥廠 抗cd74抗體藥物結合物及其使用方法
WO2025215536A1 (en) 2024-04-10 2025-10-16 Novartis Ag Macrocyclic panras inhibitors for the treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932590A (en) * 1996-12-05 1999-08-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
MXPA04002243A (es) * 2001-09-19 2004-06-29 Aventis Pharma Sa Compuestos quimicos.
JP4901102B2 (ja) 2002-05-03 2012-03-21 エクセリクシス， インク． プロテインキナーゼモジュレーターおよびその使用方法
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
CA2577752A1 (en) 2004-08-20 2006-03-02 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
CA2682356C (en) 2007-04-16 2016-06-14 Abbott Laboratories 7-substituted indole mcl-1 inhibitors
WO2009073545A2 (en) 2007-11-30 2009-06-11 Maxthera, Inc. Tetrahydro-isoquinoline ppat inhibitors as antibacterial agents
EP2217904A4 (en) 2007-12-07 2011-12-21 Linde Ag METHOD FOR MONITORING HYDROGEN FUELING SYSTEMS
EP2252617A1 (en) 2008-02-13 2010-11-24 CGI Pharmaceuticals, Inc. 6-aryl-imidaz0[l, 2-a]pyrazine derivatives, method of making, and method of use thereof
WO2012040242A1 (en) 2010-09-22 2012-03-29 Intermune, Inc. Substituted proline inhibitors of hepatitis c virus replication
US9346795B2 (en) * 2011-05-25 2016-05-24 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic Bcl inhibitors
FR2986002B1 (fr) 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008976A1 (fr) 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"

Also Published As

Publication number Publication date
EP2807159B1 (fr) 2016-11-23
DOP2014000156A (es) 2014-10-15
MX351206B (es) 2017-10-05
CA2861160A1 (en) 2013-08-01
AU2013213474B2 (en) 2017-06-08
AP4028A (en) 2017-02-04
US9120791B2 (en) 2015-09-01
KR101946911B1 (ko) 2019-02-12
CN104144930B (zh) 2017-02-22
NZ626942A (en) 2016-07-29
TWI476198B (zh) 2015-03-11
PY1302437A (es) 2015-11-02
CY1118547T1 (el) 2017-07-12
EA201400833A1 (ru) 2014-12-30
MX2014008913A (es) 2015-01-19
HUE031895T2 (hu) 2017-08-28
MD4490C1 (ro) 2018-01-31
AP2014007882A0 (en) 2014-08-31
FR2986002A1 (fr) 2013-07-26
WO2013110890A1 (fr) 2013-08-01
FR2986002B1 (fr) 2014-02-21
DK2807159T3 (en) 2017-02-27
LT2807159T (lt) 2017-01-10
ZA201405101B (en) 2015-12-23
PE20141405A1 (es) 2014-10-20
PH12014501488B1 (en) 2014-09-22
RU2014134388A (ru) 2016-03-27
ES2616679T3 (es) 2017-06-14
IL233663A0 (en) 2014-08-31
TN2014000283A1 (fr) 2015-09-30
BR112014018165A8 (pt) 2017-07-11
SI2807159T1 (sl) 2017-03-31
PL2807159T3 (pl) 2017-04-28
KR20140129052A (ko) 2014-11-06
EA026641B1 (ru) 2017-04-28
BR112014018165A2 (ro) 2017-06-20
SA113340219B1 (ar) 2015-10-14
GT201400142A (es) 2015-11-24
CA2861160C (en) 2016-08-09
CR20140311A (es) 2014-10-07
ME02601B (me) 2017-06-20
AU2013213474A1 (en) 2014-07-24
US20150051189A1 (en) 2015-02-19
GEP201606540B (en) 2016-09-12
JO3195B1 (ar) 2018-03-08
PH12014501488A1 (en) 2014-09-22
JP2015506368A (ja) 2015-03-02
CU20140089A7 (es) 2014-11-27
RU2646223C2 (ru) 2018-03-02
UA112215C2 (uk) 2016-08-10
NI201400081A (es) 2014-10-24
US9603854B2 (en) 2017-03-28
CN104144930A (zh) 2014-11-12
HK1201527A1 (en) 2015-09-04
HRP20170153T1 (hr) 2017-03-24
MD20140084A2 (en) 2014-12-31
JP5978317B2 (ja) 2016-08-24
US20150313911A1 (en) 2015-11-05
MY172811A (en) 2019-12-12
IL233663B (en) 2018-04-30
RS55739B1 (sr) 2017-07-31
ECSP14008606A (es) 2015-07-31
CL2014001829A1 (es) 2015-01-02
EP2807159A1 (fr) 2014-12-03
MA35903B1 (fr) 2014-12-01
PT2807159T (pt) 2017-01-05
TW201335157A (zh) 2013-09-01
HK1203507A1 (en) 2015-10-30
UY34578A (es) 2013-09-02
SG11201403748RA (en) 2014-10-30
BR112014018165B1 (pt) 2020-11-17
US10258626B2 (en) 2019-04-16
AR089774A1 (es) 2014-09-17
US20170151251A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
MD4490B1 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
MD4551B1 (ro) Derivaţi pe bază de tetrahidroizochinoline şi N-(fenilfosfat)amide, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
UA115881C2 (uk) Алкоксипіразоли як активатори розчинної гуанілатциклази
JO3453B1 (ar) مشتقات البنزاميد لتثبيط نشاط abl1 و abl2 و bcr-abl1
GEP201706780B (en) Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
MD3405471T2 (ro) Noi derivați de amoniu, procedeu pentru prepararea acestora și compoziții farmaceutice care îi conțin
PH12014501719A1 (en) Pyridone derivatives
MX338114B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
EA201201663A1 (ru) Производные 2-(ариламино)-3н-имидазо[4,5-b]пиридин-6-карбоксамида и их применение в качестве ингибиторов mpges-1
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
EA201500544A1 (ru) НОВЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНТИБАКТЕРИАЛЬНЫХ АГЕНТОВ И ИНГИБИТОРОВ β-ЛАКТАМАЗ
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
PH12017500111A1 (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
CY1116439T1 (el) Τριαζολοπυριδινες
PH12013500301A1 (en) Oxadiazole inhibitors of leukotriene production
HK1210771A1 (zh) 氮杂吲哚衍生物
EA201792071A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
GEP20207070B (en) New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them
PH12015502429A1 (en) Dicarboxylic acid compound
MX367772B (es) Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk.
PH12015500373A1 (en) Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease
TH107387A (th) อนุพันธุ์พิเพอราซีนไพราโซโลไพริมิดีนตัวใหม่
TH148359A (th) ไพรโรลิดีน-2-คาร์บอกซาไมด์ที่ถูกแทนที่
GB2527958A (en) Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents

Legal Events

Date Code Title Description
FG4A Patent for invention issued
TH4A Change/correction in patent specification

Free format text: CHANGE OF APPLICANT ADDRESS

KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees